Clinical Trial Update: A Study of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP) [Phase 2]

View source ↗

Summary

A phase 2 trial evaluating nab-paclitaxel-based doublet as first-line therapy for cancer of unknown primary (unknown primary tumors).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Unknown Primary Cancer
• Unknown Primary Tumors

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Fondazione del Piemonte per l'Oncologia | Conditions: Unknown Primary Tumors | Phase 2 | Status: COMPLETED